Biotech Values

[mcbio]

Perhaps management concurs with your arithmetic but the exigencies of Zebra’s Law nonetheless mandate that the program be carried forward.

Clark is not referring to the TN/HG group, the one with the best Phase 2b results, with his 15% chance of success numbers. Given the Phase 2b results, I think it's safe to say chances of success in that patient population are much, much greater than that.

I don't see Zebra's Law coming into play with CLDX as they have an extensive pipeline; I typically reserve Zebra's Law for one or two-trick ponies. CLDX is far from that.